🇺🇸 FDA
Pipeline program

TAK-662

TAK-662-1501

Phase 2 small_molecule completed

Quick answer

TAK-662 for Congenital Protein C Deficiency is a Phase 2 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Congenital Protein C Deficiency
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials